

**CLINICAL TRIALS –CURRENTLY OPEN TO ACCRUAL**

**BREAST**

**MA.39 (CCTG):** A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER.

**GASTROINTESTINAL**

**CRC.9 (CCTG):** PHASE II/III STUDY OF Ct DNA AS A PREDICTIVE BIOMARKER IN ADJUVANT CHEMOTHERAPY IN STAGE II COLON CANCER (COBRA)

**CO.21 CHALLENGE (CCTG):** PHASE III, RCT OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH HIGH RISK STAGE II OR III COLON CANCER (CHALLENGE)

**LUNG**

**BRC.7 (CCTG):** A RANDOMIZED, PHASE III STUDY OF FIRSTLINE IMMUNOTHERAPY ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN INDUCTION/MAINTENANCE OR POSTPROGRESSION IN ADVANCED NSCLC WITH IMMUNOBIOMARKER SIGNATURE-DRIVEN ANALYSIS

**HEMATOLOGY**

**POLARGO (ROCHE):** A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-GEMOX ALONE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

**RADIOTHERAPY**

**COMET -10 (CCTG):** A RANDOMIZED PHASE III TRIAL OF SABR FOR THE COMPREHENSIVE TREATMENT OF 4-10 OLIGOMETASTATIC TUMORS

**COMET-3 (CCTG):** PHASE III RCT AND ECONOMIC EVALUATION OF SABR FOR COMPREHENSIVE TREATMENT OF 1-3 OLIGOMETASTATIC TUMORS

<b><i>Coordinator:</i></b>	Khadija Al-Harazi	ext 45703	Khadija.Al-harazi@niagarahealth.on.ca
<b><i>Clinical Trials Nurse:</i></b>	Caitlin Leblanc	ext 43806	Caitlin.Leblanc@niagarahealth.on.ca
	Bedrana Jelin		Bedrana.Jelin@niagarahealth.on.ca